Streetbeat News

Price Targets

SNY

Morgan Stanley analyst Mark Purcell has initiated coverage on Sanofi (NASDAQ:SNY) with an Equal-Weight rating and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:47 am

GSK

Morgan Stanley analyst Mark Purcell has initiated coverage on GSK (NYSE:GSK) with an Equal-Weight rating and set a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:45 am

CVX

TD Cowen analyst Jason Gabelman downgraded Chevron (NYSE:CVX) from Outperform to Market Perform and reduced the price target from $170 to $150.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:40 am

DSP

Needham analyst Laura Martin has maintained a Buy rating on Viant Technology (NASDAQ:DSP) and increased the price target from $7.5 to $10.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:37 am

BILL

Wells Fargo analyst Andrew Bauch has downgraded BILL Holdings (NYSE:BILL) from Overweight to Equal-Weight and reduced the price target from $80 to $75.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:36 am

SIRI

Wells Fargo analyst Steven Cahall has downgraded Sirius XM Holdings (SIRI) from Equal-Weight to Underweight and reduced the price target from $5 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:34 am

COIN

JP Morgan analyst Kenneth Worthington downgraded Coinbase Global (NASDAQ:COIN) from Neutral to Underweight and set a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:32 am

BNTX

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on BioNTech (NASDAQ:BNTX) but has reduced the price target from $133 to $107.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:29 am

CPE

Stifel analyst Derrick Whitfield downgraded Callon Petroleum (NYSE:CPE) from Buy to Hold and reduced the price target from $44 to $32.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:12 am

ALKT

Goldman Sachs analyst Adam Hotchkiss has downgraded Alkami Technology (NASDAQ:ALKT) from Buy to Neutral, while also raising the price target from $23 to $27.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:05 am